医学
肝细胞癌
乙型肝炎病毒
内科学
肿瘤科
乙型肝炎
免疫疗法
病毒载量
胃肠病学
癌症
免疫学
病毒
作者
Mengchao An,Wenkang Wang,Jie Zhang,Brian G. Till,Lingdi Zhao,Hao Huang,Yue Yang,Tiepeng Li,Lu Han,Xiaojie Zhang,Ping Qin,Yunjian Wang,Min Zhang,Hong Cui,Quanli Gao,Zibing Wang
标识
DOI:10.1007/s00262-022-03254-w
摘要
High hepatitis B virus (HBV) DNA level is an independent risk factor for postoperative HBV-associated liver cancer recurrence. We sought to examine whether HBV DNA level and antiviral therapy are associated with survival outcomes in patients with advanced hepatocellular carcinoma (HCC) treated with anti-programmed cell death protein 1 (PD-1)based immunotherapy.This single-institution retrospective analysis included 217 patients with advanced HBV-related HCC treated from 1 June 2018, through 30 December 2020. Baseline information was compared between patients with low and high HBV DNA levels. Overall survival (OS) and progression-free survival (PFS) were compared, and univariate and multivariate analyses were applied to identify potential risk factors for oncologic outcomes.The 217 patients included in the analysis had a median survival time of 20.6 months. Of these HBV-associated HCC patients, 165 had known baseline HBV DNA levels. Baseline HBV DNA level was not significantly associated with OS (P = 0.59) or PFS (P = 0.098). Compared to patients who did not receive antiviral therapy, patients who received antiviral therapy had significantly better OS (20.6 vs 11.1 months, P = 0.020), regardless of HBV DNA levels. Moreover, antiviral status (adjusted HR = 0.24, 95% CI 0.094-0.63, P = 0.004) was an independent protective factor for OS in a multivariate analysis of patients with HBV-related HCC.HBV viral load does not compromise the clinical outcome of patients with HBV-related HCC treated with anti-PD-1-based immunotherapy. The use of antiviral therapy significantly improves survival time of HBV-related HCC patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI